US6492411B1
(en)
|
1993-11-30 |
2002-12-10 |
G. D. Searle & Co. |
Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
|
US5466823A
(en)
|
1993-11-30 |
1995-11-14 |
G.D. Searle & Co. |
Substituted pyrazolyl benzenesulfonamides
|
RU2139281C1
(ru)
*
|
1993-11-30 |
1999-10-10 |
Джи Ди Сирл энд Компани |
Пиразолилзамещенный бензолсульфонамид или его фармацевтически приемлемая соль, фармацевтическая композиция, способ лечения от воспаления или связанного с воспалением заболевания
|
US5401765A
(en)
*
|
1993-11-30 |
1995-03-28 |
G. D. Searle |
1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
|
US6716991B1
(en)
|
1993-11-30 |
2004-04-06 |
G. D. Searle & Co. |
Process for preparing a substituted pyrazolyl benzenesulfonamide for the treatment of inflammation
|
US5696143A
(en)
*
|
1994-09-20 |
1997-12-09 |
Talley; John J. |
Benz G! indazolyl derivatives for the treatment of inflammation
|
US5908852A
(en)
*
|
1994-11-14 |
1999-06-01 |
G. D. Searle & Co. |
1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
|
PL187410B1
(pl)
*
|
1995-05-25 |
2004-07-30 |
Searle & Co |
Sposób wytwarzania 3-chlorowcoalkilo-1 H-pirazoli
|
AU5886296A
(en)
*
|
1995-06-02 |
1996-12-18 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors
|
JPH11507670A
(ja)
*
|
1995-06-12 |
1999-07-06 |
ジー.ディー.サール アンド カンパニー |
シクロオキシゲナーゼ−2インヒビターと5−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療
|
US5700816A
(en)
*
|
1995-06-12 |
1997-12-23 |
Isakson; Peter C. |
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
|
EP0833664A1
(de)
|
1995-06-12 |
1998-04-08 |
G.D. SEARLE & CO. |
Kombination aus einem cyclooxygenase-2 inhibitor und einem leukotrien b4 rezeptorantagonisten zur behandlung von entzündungen
|
US5756529A
(en)
*
|
1995-09-29 |
1998-05-26 |
G.D. Searle & Co. |
Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
|
GB9520584D0
(en)
*
|
1995-10-09 |
1995-12-13 |
Fujisawa Pharmaceutical Co |
Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
|
DE69733338T2
(de)
*
|
1996-02-13 |
2006-03-16 |
G.D. Searle & Co., Chicago |
Zubereitungen, enthaltend einen cyclooxygenase-2-inhibitor und einen leukotrien-b4-rezeptor-antagonisten
|
DE19615259A1
(de)
*
|
1996-04-18 |
1997-10-23 |
Bayer Ag |
3-Cyanoaryl-pyrazole
|
US5939069A
(en)
*
|
1996-08-23 |
1999-08-17 |
University Of Florida |
Materials and methods for detection and treatment of immune system dysfunctions
|
KR20000049138A
(ko)
|
1996-10-15 |
2000-07-25 |
윌리암스 로저 에이 |
신생물의 치료 및 예방에의 시클로옥시게나제-2 저해제의 사용방법
|
ID18983A
(id)
*
|
1996-12-04 |
1998-05-28 |
Lilly Co Eli |
Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
|
US20040072889A1
(en)
*
|
1997-04-21 |
2004-04-15 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
|
WO1998052941A1
(en)
*
|
1997-05-22 |
1998-11-26 |
G.D. Searle And Co. |
PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
|
WO1998056377A1
(en)
*
|
1997-06-13 |
1998-12-17 |
Smithkline Beecham Corporation |
Novel pyrazole and pyrazoline substituted compounds
|
US6525053B1
(en)
|
1997-08-22 |
2003-02-25 |
Abbott Laboratories |
Prostaglandin endoperoxide H synthase biosynthesis inhibitors
|
US6307047B1
(en)
*
|
1997-08-22 |
2001-10-23 |
Abbott Laboratories |
Prostaglandin endoperoxide H synthase biosynthesis inhibitors
|
BR9812162A
(pt)
*
|
1997-09-08 |
2000-07-18 |
Warner Lambert Co |
Composições analgésicas compreendendo compostos antiepiléticos e métodos para o uso das mesmas
|
US5972986A
(en)
*
|
1997-10-14 |
1999-10-26 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
|
WO1999022720A2
(en)
*
|
1997-10-31 |
1999-05-14 |
G.D. Searle & Co. |
Selective cyclooxygenase-2 inhibitors against premature labor
|
US6025353A
(en)
*
|
1997-11-19 |
2000-02-15 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
|
US6011177A
(en)
*
|
1997-11-26 |
2000-01-04 |
Aerojet-General Corporation |
Process for 4-sulfonamidolphenyl hydrazines
|
CA2313049A1
(en)
|
1997-12-17 |
1999-06-24 |
Cornell Research Foundation, Inc. |
Cyclooxygenase-2 inhibition
|
US7041694B1
(en)
|
1997-12-17 |
2006-05-09 |
Cornell Research Foundation, Inc. |
Cyclooxygenase-2 inhibition
|
NZ333399A
(en)
|
1997-12-24 |
2000-05-26 |
Sankyo Co |
Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
|
US6673832B1
(en)
*
|
1998-05-04 |
2004-01-06 |
Gudarz Davar |
Methods for identifying compounds for treating pain
|
GB9811050D0
(en)
*
|
1998-05-22 |
1998-07-22 |
Pfizer Ltd |
Pyrazoles
|
US6294558B1
(en)
*
|
1999-05-31 |
2001-09-25 |
Pfizer Inc. |
Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
|
US6727238B2
(en)
|
1998-06-11 |
2004-04-27 |
Pfizer Inc. |
Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
|
US6486203B1
(en)
|
1998-09-08 |
2002-11-26 |
Cornell Research Foundation, Inc. |
Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors
|
SA99191255B1
(ar)
*
|
1998-11-30 |
2006-11-25 |
جي دي سيرل اند كو |
مركبات سيليكوكسيب celecoxib
|
US6649645B1
(en)
*
|
1998-12-23 |
2003-11-18 |
Pharmacia Corporation |
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
|
US20040122011A1
(en)
*
|
1998-12-23 |
2004-06-24 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
|
WO2000042021A1
(en)
*
|
1999-01-14 |
2000-07-20 |
Merck Frosst Canada & Co. |
Synthesis of 4-[(5-substituted or unsubstituted phenyl) -3-substituted -1h-pyrazol -1-yl] benzenesulfonamides
|
US6403630B1
(en)
*
|
1999-01-27 |
2002-06-11 |
Cornell Research Foundation, Inc. |
Treating cancers associated with overexpression of HER-2/neu
|
US20010024664A1
(en)
*
|
1999-03-19 |
2001-09-27 |
Obukowicz Mark G. |
Selective COX-2 inhibition from edible plant extracts
|
IL136025A0
(en)
*
|
1999-05-14 |
2001-05-20 |
Pfizer Prod Inc |
Combination therapy for the treatment of migraine
|
CO5190678A1
(es)
*
|
1999-06-30 |
2002-08-29 |
Pfizer Prod Inc |
Terapia combinada para el tratamiento de la migrana
|
CO5190664A1
(es)
|
1999-06-30 |
2002-08-29 |
Pfizer Prod Inc |
Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
|
ES2159479B1
(es)
*
|
1999-10-25 |
2002-05-01 |
Menarini Lab |
Nuevos indazoles como inhibidores de la ciclooxigenasa-ii
|
ES2236007T3
(es)
|
1999-12-08 |
2005-07-16 |
Pharmacia Corporation |
Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido.
|
UA74539C2
(en)
*
|
1999-12-08 |
2006-01-16 |
Pharmacia Corp |
Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
|
CN1376146B
(zh)
*
|
1999-12-08 |
2011-04-06 |
法马西亚公司 |
提高了生物利用率的雪列柯西的固态形式
|
US20030054954A1
(en)
*
|
1999-12-30 |
2003-03-20 |
Jean-Yves Chane-Ching |
Method for preparing a mesostructured material from particles with nanometric dimensions
|
EP1259504A1
(de)
*
|
2000-03-03 |
2002-11-27 |
Pfizer Products Inc. |
Pyrazole ether derivate gegen entzündung und als analgetika
|
CA2409123A1
(en)
*
|
2000-06-08 |
2001-12-13 |
The University Of Texas System |
Heterocycle derivatives and methods of use
|
DE10032132A1
(de)
*
|
2000-07-01 |
2002-01-17 |
Lohmann Therapie Syst Lts |
Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
|
AU5754701A
(en)
*
|
2000-07-13 |
2002-01-30 |
Pharmacia Corp |
Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
|
US6716829B2
(en)
|
2000-07-27 |
2004-04-06 |
Pharmacia Corporation |
Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
|
AU2001285334A1
(en)
*
|
2000-08-29 |
2002-03-13 |
Peter Van Patten |
Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
|
US20030219461A1
(en)
*
|
2000-09-12 |
2003-11-27 |
Britten Nancy J. |
Parenteral combination therapy for infective conditions
|
JP2004508401A
(ja)
*
|
2000-09-18 |
2004-03-18 |
メルク エンド カムパニー インコーポレーテッド |
シクロオキシゲナーゼ−2阻害剤およびインテグリンアルファ−vアンタゴニストの組合せを用いる炎症の治療
|
EP1337255A4
(de)
*
|
2000-10-19 |
2006-01-25 |
Smithkline Beecham Corp |
Verwendung von p38-inhibitoren zur behandlung von durch entzündungen verstärktem husten
|
US20020122836A1
(en)
*
|
2000-12-15 |
2002-09-05 |
Pharmacia Corporation |
Selective COX-2 inhibition from non-edible plant extracts
|
AU2002229074A1
(en)
*
|
2000-12-15 |
2002-06-24 |
Pharmacia Corporation |
Selective cox-2 inhibition from plant extracts
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
CA2435350A1
(en)
*
|
2001-02-02 |
2002-08-15 |
Pharmacia Corporation |
Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
|
US7012098B2
(en)
*
|
2001-03-23 |
2006-03-14 |
Pharmacia Corporation |
Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
|
MY137736A
(en)
|
2001-04-03 |
2009-03-31 |
Pharmacia Corp |
Reconstitutable parenteral composition
|
US6673818B2
(en)
|
2001-04-20 |
2004-01-06 |
Pharmacia Corporation |
Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
|
WO2002089798A2
(en)
*
|
2001-05-04 |
2002-11-14 |
Merck & Co., Inc. |
Method and compositions for treating migraines
|
US20030153801A1
(en)
*
|
2001-05-29 |
2003-08-14 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
|
EA200301200A1
(ru)
*
|
2001-05-31 |
2004-06-24 |
Фармация Корпорейшн |
Проникающая через кожу композиция селективного ингибитора циклооксигеназы-2
|
US20060167074A1
(en)
*
|
2001-06-19 |
2006-07-27 |
Norbert Muller |
Methods and compositions for the treatment of psychiatric disorders
|
DE10129320A1
(de)
*
|
2001-06-19 |
2003-04-10 |
Norbert Mueller |
Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
US20030220376A1
(en)
*
|
2001-08-10 |
2003-11-27 |
Pharmacia Corporation |
Methods for treating carbonic anhydrase mediated disorders
|
US20040067992A1
(en)
*
|
2001-08-10 |
2004-04-08 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
|
US20030100594A1
(en)
*
|
2001-08-10 |
2003-05-29 |
Pharmacia Corporation |
Carbonic anhydrase inhibitor
|
US20050101563A1
(en)
*
|
2001-08-14 |
2005-05-12 |
Pharmacia Corporation |
Method and compositions for the treatment and prevention of pain and inflammation
|
US20030114416A1
(en)
*
|
2001-08-14 |
2003-06-19 |
Pharmacia Corporation |
Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
EP1436259A1
(de)
*
|
2001-09-10 |
2004-07-14 |
Congxin Liang |
3-(4,5,6,7-tetrahydroindol-2-yl methylidien)-2-indolinonderivate als kinaseinhibitoren
|
US6906196B2
(en)
*
|
2001-09-18 |
2005-06-14 |
Onconova Therapeutics, Inc. |
Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles
|
US20030114483A1
(en)
*
|
2001-09-18 |
2003-06-19 |
Pharmacia Corporation |
Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
US6579988B2
(en)
|
2001-09-18 |
2003-06-17 |
Onconova Therapeutics, Inc. |
Processes for the preparation of 1,5-diarylpyrazoles
|
US20030236308A1
(en)
*
|
2001-09-18 |
2003-12-25 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
EP1444207A2
(de)
*
|
2001-09-19 |
2004-08-11 |
Pharmacia Corporation |
Substituierte pyrazolylverbindungen zur behandlung von entzündungen
|
WO2003024936A1
(en)
*
|
2001-09-19 |
2003-03-27 |
Pharmacia Corporation |
Substituted pyrazolo compounds for the treatment of inflammation
|
EP1578721A2
(de)
*
|
2001-10-12 |
2005-09-28 |
Onconova Therapeutics, Inc. |
Verfahren zur herstellung von substituierten isoxazolen und 2-isoxazolinen
|
US20040097473A1
(en)
*
|
2001-10-19 |
2004-05-20 |
Griswold Don E |
Use of p38 inhibitors for the treatment of smoke inhalation
|
WO2003035063A1
(en)
*
|
2001-10-25 |
2003-05-01 |
Dinesh Shantilal Patel |
Novel preparation of selective cyclooxygenase ii inhibitors
|
WO2003049678A2
(en)
|
2001-12-06 |
2003-06-19 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
DE10162121A1
(de)
*
|
2001-12-12 |
2003-06-18 |
Berolina Drug Dev Ab Svedala |
Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
|
US20040082940A1
(en)
*
|
2002-10-22 |
2004-04-29 |
Michael Black |
Dermatological apparatus and method
|
US20040126438A1
(en)
*
|
2001-12-13 |
2004-07-01 |
Obukowicz Mark G. |
Selective cox-2 inhibition from plant extracts
|
US20040062823A1
(en)
*
|
2001-12-13 |
2004-04-01 |
Obukowicz Mark G. |
Selective cox-2 inhibition from non-edible plant extracts
|
RU2004121147A
(ru)
*
|
2002-01-10 |
2005-04-10 |
Фармация Энд Апджон Компани (Us) |
Применение ингибиторов сох-2 в сочетании с противовирусными агентами для лечения инфекции вируса папилломы
|
US20030212138A1
(en)
*
|
2002-01-14 |
2003-11-13 |
Pharmacia Corporation |
Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
|
US20030220374A1
(en)
*
|
2002-01-14 |
2003-11-27 |
Pharmacia Corporation |
Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
|
TW200403072A
(en)
*
|
2002-01-23 |
2004-03-01 |
Upjohn Co |
Combination therapy for the treatment of bacterial infections
|
US20090088443A1
(en)
*
|
2002-02-15 |
2009-04-02 |
Julius Remenar |
Novel crystalline forms of conazoles and methods of making and using the same
|
US20100311701A1
(en)
*
|
2002-02-15 |
2010-12-09 |
Transform Pharmaceuticals, Inc |
Pharmaceutical Co-Crystal Compositions
|
US7927613B2
(en)
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
US7790905B2
(en)
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
EP1480639A1
(de)
*
|
2002-02-22 |
2004-12-01 |
Warner-Lambert Company LLC |
Kombinationen eines alpha-2-delta-liganden mit einem selektiven cyclooxygenase-2-hemmer
|
IL163846A0
(en)
*
|
2002-03-01 |
2005-12-18 |
Univ South Florida |
Multiple-component solid phases containing at least one active pharmaceutical ingredient
|
TW562937B
(en)
*
|
2002-03-26 |
2003-11-21 |
Nanya Technology Corp |
Method for fast determining defect type of word line
|
JP2005528384A
(ja)
*
|
2002-04-08 |
2005-09-22 |
ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション |
増殖性細胞においてアポトーシスを誘導するための化合物および方法
|
IL164163A0
(en)
*
|
2002-04-09 |
2005-12-18 |
Pharmacia Corp |
Process for preparing a finely self-emulsifiable pharmaceutical composition
|
US7090829B2
(en)
*
|
2002-04-11 |
2006-08-15 |
Carbomer, Inc. |
Imaging probes
|
JP2005522495A
(ja)
|
2002-04-11 |
2005-07-28 |
カルボマー インク |
新規な糖尿病イメージングプローブ
|
US20040006100A1
(en)
*
|
2002-04-18 |
2004-01-08 |
Stephenson Diane T. |
Monotherapy for the treatment of parkinson's disease with cyclooxygenase-2 (COX 2) inhibitor(S)
|
JP2005528403A
(ja)
*
|
2002-04-18 |
2005-09-22 |
ファルマシア・コーポレーション |
シクロオキシゲナーゼ−2(cox2)阻害薬によるパーキンソン病処置のための併用療法
|
MXPA04010397A
(es)
*
|
2002-04-22 |
2005-02-17 |
Pfizer Prod Inc |
Inhibidores selectivos de la ciclooxigenasa-2.
|
WO2003095623A2
(en)
*
|
2002-05-10 |
2003-11-20 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
|
JP2006511499A
(ja)
*
|
2002-05-13 |
2006-04-06 |
ファルマシア コーポレイション |
安定な無定形セレコキシブ複合物およびその製法
|
KR100804827B1
(ko)
*
|
2002-05-17 |
2008-02-20 |
씨제이제일제당 (주) |
티아졸리딘-4-온 유도체, 그 제조방법 및 약제학적 조성물
|
WO2003099794A1
(en)
*
|
2002-05-24 |
2003-12-04 |
Pharmacia Corporation |
Synthesis of diaryl pyrazoles
|
US20070059356A1
(en)
*
|
2002-05-31 |
2007-03-15 |
Almarsson Oern |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
US20030225054A1
(en)
*
|
2002-06-03 |
2003-12-04 |
Jingwu Duan |
Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
|
JP2006500377A
(ja)
*
|
2002-06-21 |
2006-01-05 |
トランスフォーム・ファーマシューティカルズ・インコーポレイテッド |
改善された溶解性を有する医薬組成物
|
KR100478467B1
(ko)
|
2002-06-24 |
2005-03-23 |
씨제이 주식회사 |
피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물
|
KR100465455B1
(ko)
*
|
2002-06-24 |
2005-01-13 |
씨제이 주식회사 |
2-티옥소티아졸 유도체, 그 제조방법 및 약제학적 조성물
|
ITMI20021391A1
(it)
|
2002-06-25 |
2003-12-29 |
Nicox Sa |
Nitroderivati di inibitori della cicloossigenasi-2
|
JP2005535642A
(ja)
*
|
2002-06-28 |
2005-11-24 |
ニトロメッド インコーポレーティッド |
オキシムおよび/またはヒドラゾンを含有するニトロソ化および/またはニトロシル化シクロオキシゲナーゼ−2選択的阻害剤、組成物、および使用方法
|
EP1536863A1
(de)
*
|
2002-07-02 |
2005-06-08 |
Pharmacia Corporation |
Verwendung von cyclooxygenase-2-selektiven hemmern und thrombolytischen mitteln zur behandlung oder prävention eines vasookklusiven ereignisses
|
KR100467668B1
(ko)
*
|
2002-08-07 |
2005-01-24 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
US7112605B2
(en)
*
|
2002-08-08 |
2006-09-26 |
Research Institute of Materia Medica Chinese Acadamy of Medical Sciences |
Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
US20060052432A1
(en)
*
|
2002-09-20 |
2006-03-09 |
Julius Remenar |
Pharmaceutical compositions with improved dissolution
|
KR100484525B1
(ko)
|
2002-10-15 |
2005-04-20 |
씨제이 주식회사 |
이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
|
US8455458B2
(en)
|
2002-10-16 |
2013-06-04 |
Arthrodynamic Technologies, Animal Health Division, Inc. |
Composition and method for treating connective tissue damage
|
US7803787B2
(en)
|
2002-10-16 |
2010-09-28 |
Arthrodynamic Technologies, Animal Health Division, Inc. |
Composition and method for treating connective tissue damage by transmucosal administration
|
AU2003278039A1
(en)
*
|
2002-10-22 |
2004-05-13 |
Merck Frosst Canada And Co. |
Nitric oxide releasing selective cyclooxygenase-2 inhibitors
|
US20040082543A1
(en)
*
|
2002-10-29 |
2004-04-29 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
|
WO2004043358A2
(en)
*
|
2002-11-08 |
2004-05-27 |
Bristol-Myers Squibb Company |
Formulations of low solubility bioactive agents and processes for making the same
|
US20040147581A1
(en)
*
|
2002-11-18 |
2004-07-29 |
Pharmacia Corporation |
Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
|
KR100470075B1
(ko)
*
|
2002-11-21 |
2005-02-05 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
AU2003295846A1
(en)
*
|
2002-11-26 |
2004-06-18 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical formulations of celcoxib
|
KR100491317B1
(ko)
*
|
2002-11-26 |
2005-05-24 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
KR100470076B1
(ko)
*
|
2002-11-27 |
2005-02-05 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
KR20090118994A
(ko)
|
2002-12-13 |
2009-11-18 |
워너-램버트 캄파니 엘엘씨 |
하부요로증상을 치료하기 위한 알파-2-델타 리간드
|
US20040204411A1
(en)
*
|
2002-12-17 |
2004-10-14 |
Pharmacia Corporation |
Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
|
US20040235925A1
(en)
*
|
2002-12-17 |
2004-11-25 |
Pharmacia Corporation |
Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
|
US20080153894A1
(en)
*
|
2002-12-19 |
2008-06-26 |
Pharmacia Corporation |
Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
|
AU2003297397A1
(en)
*
|
2002-12-19 |
2004-07-14 |
Pharmacia Corp |
Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
|
WO2004058354A1
(en)
*
|
2002-12-20 |
2004-07-15 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
|
US8183290B2
(en)
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
EP2339328A3
(de)
|
2002-12-30 |
2011-07-13 |
Transform Pharmaceuticals, Inc. |
Pharmazeutische kokristallisierte Celecoxib-Zusammensetzungen
|
US20050026902A1
(en)
*
|
2003-01-31 |
2005-02-03 |
Timothy Maziasz |
Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
|
US20040176378A1
(en)
*
|
2003-02-12 |
2004-09-09 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system
|
US20070265606A1
(en)
*
|
2003-02-14 |
2007-11-15 |
Reliant Technologies, Inc. |
Method and Apparatus for Fractional Light-based Treatment of Obstructive Sleep Apnea
|
SI1608407T1
(sl)
*
|
2003-03-20 |
2006-12-31 |
Pharmacia Corp |
Razprsljiva formulacija protivnetnega sredstva
|
US20050009931A1
(en)
*
|
2003-03-20 |
2005-01-13 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
US20040214753A1
(en)
*
|
2003-03-20 |
2004-10-28 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
US20050004098A1
(en)
*
|
2003-03-20 |
2005-01-06 |
Britten Nancy Jean |
Dispersible formulation of an anti-inflammatory agent
|
US20040220155A1
(en)
*
|
2003-03-28 |
2004-11-04 |
Pharmacia Corporation |
Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
|
US20040214861A1
(en)
*
|
2003-03-28 |
2004-10-28 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
|
US20060142368A1
(en)
*
|
2003-04-08 |
2006-06-29 |
Ching-Shih Chen |
Compounds and methods for inducing apoptosis in proliferating cells
|
ATE487474T1
(de)
*
|
2003-04-15 |
2010-11-15 |
Wellstat Therapeutics Corp |
Verbindungen zur behandlung von stoffwechselstörungen
|
US20050009733A1
(en)
*
|
2003-04-22 |
2005-01-13 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
|
US20040220187A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
|
WO2004093816A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
|
US20040229803A1
(en)
*
|
2003-04-22 |
2004-11-18 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
|
US20060135506A1
(en)
*
|
2003-04-22 |
2006-06-22 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
|
US20040224940A1
(en)
*
|
2003-04-22 |
2004-11-11 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of central nervous system damage
|
CN1777576A
(zh)
|
2003-04-22 |
2006-05-24 |
维尔斯达医疗公司 |
用于治疗代谢紊乱的化合物
|
WO2004100895A2
(en)
*
|
2003-05-13 |
2004-11-25 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
|
WO2004103286A2
(en)
*
|
2003-05-14 |
2004-12-02 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cholimergic agent
|
US20050159419A1
(en)
*
|
2003-05-14 |
2005-07-21 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
|
MXPA05012280A
(es)
*
|
2003-05-14 |
2006-02-10 |
Pharmacia Corp |
Composiciones de una bencenosulfonamida o un metilsulfonilbenceno, inhibidores selectivos de ciclooxigenasa-2 y un agente colinergico para el tratamiento de flujo sanguineo reducido o traumatismo en el sistema nervioso central.
|
US20050113376A1
(en)
*
|
2003-05-27 |
2005-05-26 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor, a xanthine compound and an alcohol for the treatment of ischemic mediated central nervous system disorders or injury
|
US20060160776A1
(en)
*
|
2003-05-28 |
2006-07-20 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
|
EP2319843B1
(de)
|
2003-05-30 |
2013-04-03 |
Ranbaxy Laboratories Limited |
Substituirte Pyrrolderivate und Ihre Verwendung als HMG-CO-Hemmer
|
US20050070524A1
(en)
*
|
2003-06-06 |
2005-03-31 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
|
US20050054646A1
(en)
*
|
2003-06-09 |
2005-03-10 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders
|
JP2007522084A
(ja)
*
|
2003-06-24 |
2007-08-09 |
ファルマシア・コーポレーション |
悪心を伴う片頭痛の治療
|
WO2005007156A1
(en)
*
|
2003-07-10 |
2005-01-27 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin ii receptor antagonist for the treatment of central nervous system damage
|
WO2005007106A2
(en)
*
|
2003-07-10 |
2005-01-27 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a non-nmda glutamate modulator for the treatment of central nervous system damage
|
WO2005018541A2
(en)
*
|
2003-07-11 |
2005-03-03 |
Pharmacia Corporation |
Cox-2 inhibitor and serotonin modulator for treating cns damage
|
WO2005009342A2
(en)
*
|
2003-07-16 |
2005-02-03 |
Pharmacia Corporation |
Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
|
WO2005009354A2
(en)
*
|
2003-07-17 |
2005-02-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an ikk inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury
|
AU2004266705A1
(en)
*
|
2003-08-20 |
2005-03-03 |
Nitromed, Inc. |
Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
|
US20050119262A1
(en)
*
|
2003-08-21 |
2005-06-02 |
Pharmacia Corporation |
Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
|
WO2005018563A2
(en)
*
|
2003-08-22 |
2005-03-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
|
US20050107350A1
(en)
*
|
2003-08-22 |
2005-05-19 |
Pharmacia Corporation |
Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
|
MXPA06002112A
(es)
*
|
2003-08-22 |
2006-05-17 |
Pharmacia Corp |
Composiciones de un inhibidor selectivo de ciclooxigenasa-2 y un agente modulador de serotonina para el tratamiento de neoplasia.
|
WO2005018564A2
(en)
*
|
2003-08-22 |
2005-03-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
|
WO2005020910A2
(en)
*
|
2003-08-27 |
2005-03-10 |
Pharmacia Corporation |
Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
WO2005023183A2
(en)
*
|
2003-08-28 |
2005-03-17 |
Nitromed, Inc. |
Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
|
WO2005023189A2
(en)
*
|
2003-09-03 |
2005-03-17 |
Pharmacia Corporation |
Method of cox-2 selective inhibitor and nitric oxide-donating agent
|
US20050131028A1
(en)
*
|
2003-09-11 |
2005-06-16 |
Pharmacia Corporation |
Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
|
US20060079566A1
(en)
*
|
2003-10-03 |
2006-04-13 |
Ching-Shih Chen |
PDK-1/Akt signaling inhibitors
|
WO2005037193A2
(en)
*
|
2003-10-03 |
2005-04-28 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury
|
WO2005044227A1
(en)
*
|
2003-11-05 |
2005-05-19 |
Glenmark Pharmaceuticals Limited |
Topical pharmaceutical compositions
|
US20050100594A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Nilendu Sen |
Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
|
BRPI0415939A
(pt)
*
|
2003-11-12 |
2007-01-02 |
Pharmacia & Upjohn Co Llc |
composições de um inibidor seletivo da ciclooxigenase-2 e um agente de modulação do fator neurotrófico para o tratamento de distúrbios mediados pelo sistema nervoso central
|
AU2003284759A1
(en)
*
|
2003-11-25 |
2005-06-17 |
Cj Corporation |
Thione derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
|
US7671072B2
(en)
*
|
2003-11-26 |
2010-03-02 |
Pfizer Inc. |
Aminopyrazole derivatives as GSK-3 inhibitors
|
JPWO2005054181A1
(ja)
*
|
2003-12-01 |
2007-12-06 |
株式会社リバース・プロテオミクス研究所 |
抗癌剤の新規標的タンパク質および対応する新規抗癌剤(スプナール)
|
US7067159B2
(en)
*
|
2003-12-05 |
2006-06-27 |
New Chapter, Inc. |
Methods for treating prostate cancer with herbal compositions
|
US20090131342A1
(en)
*
|
2004-01-22 |
2009-05-21 |
Nitromed, Inc. |
Nitrosated and/or nitrosylated compounds, compositions and methods of use
|
JP2007518788A
(ja)
|
2004-01-22 |
2007-07-12 |
ファイザー・インク |
バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
|
EP1742922B1
(de)
*
|
2004-04-01 |
2016-02-03 |
Zoetis Services LLC |
Kristallines Pyrazolderivat
|
MXPA06012510A
(es)
*
|
2004-04-28 |
2006-12-15 |
Pfizer |
Derivados de 3-heterociclil-4-fenil-triazol como inhibidores del receptor de vasopresina via.
|
US7507823B2
(en)
*
|
2004-05-06 |
2009-03-24 |
Bristol-Myers Squibb Company |
Process of making aripiprazole particles
|
ITMI20041032A1
(it)
*
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Compositi farmaceutici
|
CA2571807A1
(en)
|
2004-07-01 |
2006-01-19 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
MX2007000749A
(es)
*
|
2004-07-22 |
2007-03-28 |
Pharmacia Corp |
Composiciones para el tratamiento de inflamacion y dolor usando una combinacion de un aine y un antagonista del receptor de ltb4.
|
US7622142B2
(en)
*
|
2004-09-14 |
2009-11-24 |
New Chapter Inc. |
Methods for treating glioblastoma with herbal compositions
|
WO2006041855A2
(en)
|
2004-10-04 |
2006-04-20 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
US9051342B2
(en)
|
2004-10-13 |
2015-06-09 |
Ptc Therapeutics, Inc. |
Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases
|
AU2005304770A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Nicox S.A. |
Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
|
JP2008520578A
(ja)
*
|
2004-11-15 |
2008-06-19 |
ニトロメッド インコーポレーティッド |
複素環式の酸化窒素供与体基を含む利尿化合物、組成物および使用方法
|
BRPI0519398A2
(pt)
|
2004-12-23 |
2009-01-20 |
Glaxo Group Ltd |
compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina
|
WO2006078995A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Nitromed, Inc. |
Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
|
AU2006336387A1
(en)
*
|
2005-02-16 |
2007-08-02 |
Nicox S.A. |
Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
|
JP2008531697A
(ja)
*
|
2005-02-28 |
2008-08-14 |
ニトロメッド インコーポレーティッド |
酸化窒素増強基を含む心血管化合物、組成物および使用法
|
WO2006099058A2
(en)
*
|
2005-03-09 |
2006-09-21 |
Nitromed, Inc. |
Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
|
CA2604357C
(en)
|
2005-04-26 |
2012-01-17 |
Pfizer Inc. |
P-cadherin antibodies
|
US20060251702A1
(en)
*
|
2005-05-05 |
2006-11-09 |
Cook Biotech Incorporated |
Implantable materials and methods for inhibiting tissue adhesion formation
|
ES2382814T3
(es)
|
2005-05-17 |
2012-06-13 |
Merck Sharp & Dohme Ltd. |
Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
|
CA2608718A1
(en)
*
|
2005-05-18 |
2006-11-23 |
Pfizer Limited |
1, 2, 4-triazole derivatives as vasopressin antagonists
|
US20090048219A1
(en)
*
|
2005-05-23 |
2009-02-19 |
Nitromed Inc. |
Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
|
KR20080028964A
(ko)
|
2005-06-27 |
2008-04-02 |
엑셀리시스, 인코포레이티드 |
피라졸계 lxr 변조제
|
EP1915157A4
(de)
|
2005-08-02 |
2010-09-01 |
Nicox Sa |
Stickoxidverstärkende antimikrobielle verbindungen, zusammensetzungen und verwendungsverfahren
|
TW200804345A
(en)
|
2005-08-30 |
2008-01-16 |
Novartis Ag |
Substituted benzimidazoles and methods of preparation
|
AU2006297571B2
(en)
|
2005-09-07 |
2012-03-15 |
Amgen Fremont Inc. |
Human monoclonal antibodies to activin receptor-like kinase-1
|
WO2007041681A2
(en)
*
|
2005-10-04 |
2007-04-12 |
Nitromed, Inc. |
Methods for treating respiratory disorders
|
EP1775723A1
(de)
*
|
2005-10-13 |
2007-04-18 |
Deutsche Thomson-Brandt Gmbh |
Holografisches Speichermedium
|
SG166829A1
(en)
|
2005-11-08 |
2010-12-29 |
Ranbaxy Lab Ltd |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
US7838023B2
(en)
*
|
2005-11-16 |
2010-11-23 |
Nitromed, Inc. |
Furoxan compounds, compositions and methods of use
|
WO2007075541A2
(en)
*
|
2005-12-20 |
2007-07-05 |
Nitromed, Inc. |
Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
|
WO2007075542A2
(en)
*
|
2005-12-22 |
2007-07-05 |
Nitromed, Inc. |
Nitric oxide enhancing pyruvate compounds, compositions and methods of use
|
US20070154542A1
(en)
*
|
2005-12-30 |
2007-07-05 |
Cogentus Pharmaceuticals, Inc. |
Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
|
WO2007087246A2
(en)
|
2006-01-24 |
2007-08-02 |
Merck & Co., Inc. |
Jak2 tyrosine kinase inhibition
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US8067414B2
(en)
|
2006-03-29 |
2011-11-29 |
Nicox S.A. |
Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
|
TW200813039A
(en)
|
2006-04-19 |
2008-03-16 |
Novartis Ag |
6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
|
JP4383525B2
(ja)
|
2006-05-09 |
2009-12-16 |
ファイザー・プロダクツ・インク |
シクロアルキルアミノ酸誘導体およびその医薬組成物
|
US8128460B2
(en)
*
|
2006-09-14 |
2012-03-06 |
The Material Works, Ltd. |
Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
|
AU2007300627B2
(en)
|
2006-09-22 |
2012-02-16 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20080208179A1
(en)
*
|
2006-10-26 |
2008-08-28 |
Reliant Technologies, Inc. |
Methods of increasing skin permeability by treatment with electromagnetic radiation
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
AU2007333194A1
(en)
|
2006-12-08 |
2008-06-19 |
Exelixis, Inc. |
LXR and FXR modulators
|
EA017171B1
(ru)
|
2006-12-22 |
2012-10-30 |
Рекордати Айерленд Лимитед |
КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ αδ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП)
|
GEP20115337B
(en)
|
2007-01-10 |
2011-11-25 |
St Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
JP2010516679A
(ja)
*
|
2007-01-19 |
2010-05-20 |
マリンクロット インコーポレイテッド |
診断用および治療用シクロオキシゲナーゼ−2結合リガンド
|
MX2009009304A
(es)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso.
|
GB0704407D0
(en)
|
2007-03-07 |
2007-04-18 |
Glaxo Group Ltd |
Compounds
|
US7919633B2
(en)
*
|
2007-03-19 |
2011-04-05 |
Dr. Reddy's Laboratories Limited |
Process for preparation of celecoxib
|
AU2008254425A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
CSF-1R inhibitors, compositions, and methods of use
|
US9186375B2
(en)
|
2007-06-21 |
2015-11-17 |
Arthrodynamic Technologies, Animal Health Division, Inc. |
Glycosaminoglycan compositions in combination with stem cells
|
EP3103791B1
(de)
|
2007-06-27 |
2018-01-31 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino-derivate als histondeacetylase-hemmer
|
HU227970B1
(en)
*
|
2007-07-10 |
2012-07-30 |
Egis Gyogyszergyar Nyrt |
Pharmaceutical compositions containing silicones of high volatility
|
MX2010000465A
(es)
|
2007-07-12 |
2010-08-30 |
Tragara Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
|
US7943658B2
(en)
*
|
2007-07-23 |
2011-05-17 |
Bristol-Myers Squibb Company |
Indole indane amide compounds useful as CB2 agonists and method
|
US8039502B2
(en)
|
2007-07-24 |
2011-10-18 |
The Ohio State University Research Foundation |
Anti-infective agents against intracellular pathogens
|
US20090062364A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched celecoxib
|
US8263641B2
(en)
|
2007-09-10 |
2012-09-11 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US8598184B2
(en)
|
2008-03-03 |
2013-12-03 |
Tiger Pharmatech |
Protein kinase inhibitors
|
US7618539B2
(en)
*
|
2008-03-31 |
2009-11-17 |
Ampac Fine Chemicals Llc |
Simulated moving bed chromatography for strongly retained compounds
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
WO2010027875A2
(en)
|
2008-08-27 |
2010-03-11 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
EP2177215A1
(de)
|
2008-10-17 |
2010-04-21 |
Laboratorios Del. Dr. Esteve, S.A. |
Co-Kristalle von Tramadol und NSARs
|
US8785466B2
(en)
*
|
2008-10-31 |
2014-07-22 |
Loyola University Chicago |
Methods of using proteinacious channels to identify pharmaceutical treatments and risks, and treatments resulting therefrom
|
US8686017B2
(en)
*
|
2008-10-31 |
2014-04-01 |
Loyola University Chicago |
Methods of using proteinacious channels to identify pharmaceutical treatments and risks, and treatments resulting therefrom
|
WO2010095024A2
(en)
|
2009-02-20 |
2010-08-26 |
Aurobindo Pharma Limited |
An improved process for the preparation of celecoxib
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
US20120108823A1
(en)
|
2009-04-22 |
2012-05-03 |
The Ohio State University Research Foundation |
Anti-francisella agents
|
WO2010150144A2
(en)
|
2009-06-25 |
2010-12-29 |
Wockhardt Research Centre |
Low dose pharmaceutical compositions of celecoxib
|
WO2011012622A1
(en)
|
2009-07-30 |
2011-02-03 |
Glaxo Group Limited |
Benzoxazinone derivatives for the treatment of glytl mediated disorders
|
WO2011023753A1
(en)
|
2009-08-27 |
2011-03-03 |
Glaxo Group Limited |
Benzoxazine derivatives as glycine transport inhibitors
|
UA109417C2
(uk)
|
2009-10-14 |
2015-08-25 |
Мерк Шарп Енд Доме Корп. |
ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
|
WO2011055233A2
(en)
|
2009-11-03 |
2011-05-12 |
Actavis Group Ptc Ehf |
Improved process for preparing celecoxib polymorph
|
GB201000685D0
(en)
|
2010-01-15 |
2010-03-03 |
Glaxo Group Ltd |
Novel compounds
|
US20110213159A1
(en)
|
2010-03-01 |
2011-09-01 |
Vamsee Krishna Muppidi |
Process for preparation of celecoxib crystalline form
|
CA2829790C
(en)
|
2010-03-30 |
2018-06-05 |
Verseon Corporation |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
JP2013525448A
(ja)
|
2010-04-27 |
2013-06-20 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
WO2011139489A2
(en)
|
2010-04-27 |
2011-11-10 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
GB201007791D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel compounds
|
GB201007789D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
US20130072519A1
(en)
|
2010-05-21 |
2013-03-21 |
Edward Lee Conn |
2-phenyl benzoylamides
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
EP2590953B1
(de)
|
2010-07-09 |
2014-10-29 |
Convergence Pharmaceuticals Limited |
Tetrazolverbindungen als calciumkanalblocker
|
AU2011285909B2
(en)
|
2010-08-02 |
2016-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
RU2745848C2
(ru)
|
2010-08-17 |
2021-04-01 |
Сирна Терапьютикс, Инк. |
ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
AU2011293201B2
(en)
|
2010-08-27 |
2015-11-05 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
EP2613782B1
(de)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
EP2615916B1
(de)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Kondensierte pyrazolderivate als neue erk-hemmer
|
EP3327125B1
(de)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
|
US9079899B2
(en)
|
2010-11-01 |
2015-07-14 |
The Ohio State University |
Anti-staphylococcal celecoxib derivatives
|
US9096532B2
(en)
|
2010-12-13 |
2015-08-04 |
The Regents Of The University Of California |
Pyrazole inhibitors of COX-2 and sEH
|
EP2654748B1
(de)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
ES2541416T3
(es)
|
2011-01-19 |
2015-07-20 |
Convergence Pharmaceuticals Limited |
Derivados de piperazina como bloqueadores de los canales de calcio Cav2.2
|
US20130345392A1
(en)
|
2011-03-04 |
2013-12-26 |
Pfizer Inc |
Edn3-like peptides and uses thereof
|
EP2685969A4
(de)
|
2011-03-18 |
2014-08-06 |
Catabasis Pharmaceuticals Inc |
Verwendung intrazellularer enzyme zur freisetzung kovalent gebundener biowirkstoffe
|
CA2831730A1
(en)
|
2011-04-21 |
2012-10-26 |
Piramal Enterprises Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
AR086745A1
(es)
|
2011-06-27 |
2014-01-22 |
Parion Sciences Inc |
3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
|
EP2770987B1
(de)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Neue verbindungen als erk-hemmer
|
WO2013066729A1
(en)
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
|
GB201122113D0
(en)
|
2011-12-22 |
2012-02-01 |
Convergence Pharmaceuticals |
Novel compounds
|
EP3919620A1
(de)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
|
EP2861562B1
(de)
|
2012-06-14 |
2018-05-09 |
Mayo Foundation For Medical Education And Research |
Pyrazolderivate als hemmer von stat3
|
US11154535B2
(en)
|
2012-07-31 |
2021-10-26 |
Egis Pharmaceuticals Plc |
Transdermal formulation containing COX inhibitors
|
US10045935B2
(en)
|
2012-07-31 |
2018-08-14 |
Egis Pharmaceuticals Plc |
Transdermal formulation containing COX inhibitors
|
US10045965B2
(en)
|
2012-07-31 |
2018-08-14 |
Egis Pharmaceuticals Plc |
Transdermal formulation containing COX inhibitors
|
JP6280554B2
(ja)
|
2012-09-28 |
2018-02-14 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Erk阻害剤である新規化合物
|
WO2014059333A1
(en)
|
2012-10-12 |
2014-04-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
KR102161331B1
(ko)
|
2012-11-28 |
2020-09-29 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 조성물 및 방법
|
ES2707305T3
(es)
|
2012-12-20 |
2019-04-03 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de HDM2
|
DK2938191T3
(en)
|
2012-12-28 |
2018-05-07 |
Dow Agrosciences Llc |
SYNERGISTIC FUNGICIDE MIXTURES FOR FERTILIZER IN GRAIN PLANTS
|
EP2951180B1
(de)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8-substituierte purine als hdm2-inhibitoren
|
US9107947B2
(en)
|
2013-01-31 |
2015-08-18 |
The Penn State Research Foundation |
Anti-cancer compositions and methods
|
CN103102306A
(zh)
*
|
2013-02-06 |
2013-05-15 |
河南东泰制药有限公司 |
一种塞来昔布的制备方法
|
US10131654B2
(en)
|
2013-03-08 |
2018-11-20 |
Translational Drug Development, Llc |
Pyrazole compounds and methods of use thereof
|
BR112015023214A8
(pt)
|
2013-03-15 |
2019-12-24 |
Verseon Corp |
composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica
|
SG10201707480PA
(en)
|
2013-03-15 |
2017-10-30 |
Verseon Corp |
Multisubstituted aromatic compounds as serine protease inhibitors
|
EP3019171B1
(de)
|
2013-07-11 |
2018-09-05 |
Merck Sharp & Dohme Corp. |
Substituierte amidopyrazolhemmer von interleukinrezeptor-assoziierten kinasen (irak-4)
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
EP2886104A1
(de)
|
2013-12-11 |
2015-06-24 |
Patir, Suleyman |
Intraartikuläres Gel
|
RU2016136430A
(ru)
|
2014-02-11 |
2018-03-15 |
Др. Редди'С Лабораторис Лтд. |
Парентеральные композиции целекоксиба
|
CN103992273B
(zh)
*
|
2014-04-18 |
2016-05-18 |
南京中医药大学 |
一种选择性非甾体抗炎镇痛药Celebrex(塞来昔布)的合成方法
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
BR112017004704A2
(pt)
|
2014-09-17 |
2018-01-23 |
Verseon Corp |
composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
|
GB201417500D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417499D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417497D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
EP3240412A4
(de)
|
2014-12-30 |
2018-04-25 |
Dow Agrosciences LLC |
Verwendung von picolinamidverbindungen mit fungizider aktivität
|
WO2016109301A1
(en)
|
2014-12-30 |
2016-07-07 |
Dow Agrosciences Llc |
Picolinamides with fungicidal activity
|
CA2972551A1
(en)
|
2014-12-30 |
2016-07-07 |
Dow Agrosciences Llc |
Use of picolinamides as fungicides
|
CN107205397A
(zh)
|
2014-12-30 |
2017-09-26 |
美国陶氏益农公司 |
具有杀真菌活性的吡啶酰胺化合物的用途
|
CN107205405B
(zh)
|
2014-12-30 |
2021-08-24 |
美国陶氏益农公司 |
具有杀真菌活性的吡啶酰胺化合物
|
ME03737B
(de)
*
|
2015-02-16 |
2021-01-20 |
Univ Queensland |
Sulfonylharnstoffe und verwandte verbindungen und verwendung davon
|
LT3261639T
(lt)
|
2015-02-27 |
2022-11-25 |
Verseon International Corporation |
Pakaitiniai pirazolo junginiai kaip serino proteazės inhibitoriai
|
US10155765B2
(en)
|
2015-03-12 |
2018-12-18 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of IRAK4 activity
|
US10040802B2
(en)
|
2015-03-12 |
2018-08-07 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of IRAK4 activity
|
US10329294B2
(en)
|
2015-03-12 |
2019-06-25 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of IRAK4 activity
|
EP3292213A1
(de)
|
2015-05-04 |
2018-03-14 |
Academisch Medisch Centrum |
Biomarker für den nachweis von aspirinunempfindlichkeit
|
MX2017015238A
(es)
|
2015-05-28 |
2018-02-19 |
Dr Reddy´S Laboratories Ltd |
Composicion oral de celecoxib para tratamiento de dolor.
|
US20190038756A1
(en)
|
2016-02-10 |
2019-02-07 |
Cocoon Biotech Inc. |
Compositions including benzenesulfonamide-containing non-steroidal anti-inflammatory drugs, silk fibroin, and a gelling agent and uses thereof
|
WO2017208069A2
(en)
|
2016-05-27 |
2017-12-07 |
Dr. Reddy's Laboratories Ltd. |
Oral composition of celecoxib for treatment of pain
|
CA3036195A1
(en)
|
2016-09-07 |
2018-03-15 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
KR20200003038A
(ko)
|
2017-05-02 |
2020-01-08 |
다우 아그로사이언시즈 엘엘씨 |
잔디풀 상의 진균 질환에 대한 살진균제로서의 비고리형 피콜린아미드 화합물의 용도
|
TWI774761B
(zh)
|
2017-05-02 |
2022-08-21 |
美商科迪華農業科技有限責任公司 |
用於穀物中的真菌防治之協同性混合物
|
TW201842851A
(zh)
|
2017-05-02 |
2018-12-16 |
美商陶氏農業科學公司 |
用於穀類中的真菌防治之協同性混合物
|
US10350171B2
(en)
|
2017-07-06 |
2019-07-16 |
Dexcel Ltd. |
Celecoxib and amlodipine formulation and method of making the same
|
CN109748872A
(zh)
*
|
2017-11-01 |
2019-05-14 |
南京大学 |
一类含二芳基吡唑骨架的吗啉衍生物抗肿瘤化合物的设计与合成
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
BR102019004480B1
(pt)
|
2018-03-08 |
2023-03-28 |
Dow Agrosciences Llc |
Picolinamidas como fungicidas
|
AU2019240299B2
(en)
*
|
2018-03-21 |
2023-06-22 |
D.E. Shaw Research, Llc |
SHP2 phosphatase inhibitors and methods of use thereof
|
US20210277009A1
(en)
|
2018-08-07 |
2021-09-09 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US20210309688A1
(en)
|
2018-08-07 |
2021-10-07 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
MX2018011142A
(es)
|
2018-09-13 |
2019-10-10 |
Federico Amezcua Amezcua |
Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona.
|
MX2021004298A
(es)
|
2018-10-15 |
2021-06-08 |
Corteva Agriscience Llc |
Metodos de sintesis de oxipicolinamidas.
|
KR20200048516A
(ko)
|
2018-10-30 |
2020-05-08 |
오토텔릭바이오 주식회사 |
복합제 의약 조성물
|
MX2018013458A
(es)
|
2018-11-05 |
2019-07-25 |
Federico Amezcua Amezcua |
Composicion farmaceutica que comprende la combinacion de un inhibidor selectivo de la ciclooxigenasa 2 y un carbamato derivado de la guaifenesina para el tratamiento del dolor, inflamacion y contractura muscular.
|
WO2020210373A1
(en)
*
|
2019-04-09 |
2020-10-15 |
Tremeau Pharmaceuticals, Inc. |
Treatment of viral hemorrhagic fevers with etoricoxib
|
AU2020354475A1
(en)
|
2019-09-24 |
2022-05-05 |
Relay Therapeutics, Inc. |
SHP2 phosphatase inhibitors and methods of making and using the same
|
AU2020408148A1
(en)
|
2019-12-17 |
2022-06-16 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
CA3144079A1
(en)
|
2020-12-28 |
2022-06-28 |
Biodelivery Sciences International, Inc. |
Methods of treating pain
|
CN113045498B
(zh)
*
|
2021-03-24 |
2023-01-24 |
江苏食品药品职业技术学院 |
一种1,5-二芳基吡唑衍生物、合成方法及用途
|
CN115838360B
(zh)
*
|
2022-12-20 |
2023-09-26 |
常州制药厂有限公司 |
一种塞来昔布的制备方法
|